Our Research
Numerous investigations suggest thatMesenchymal Stem Cells (MSCs) in general repre-sent a valuable tool for therapy of symptoms relatedto chronic inflammatory diseases. Blue HorizonStem Cell Therapy Program is a leading provider ofadult and children’s stem cell therapies. Uniquelywe have safely and efficiently treated more 600 pa-tients with documenting each procedure.Materials and methods: The purpose of our studyis primarily to monitor the immune response inorder to validate the safety of intravenous infu-sion of human umbilical cord blood derivedMSCs (UC-MSCs), and secondly, to evaluate ef-fects on biomarkers associated with chronic in-flammation. Nine patients were treated forconditions associated with chronic inflammationand for the purpose of anti-aging. They have beengiven one intravenous infusion of UC-MSCs.Results: Our study of blood test markers of 9 pa-tients with chronic inflammation before andwithin three months after MSCs treatmentdemonstrates that there is no significant changesand MSCs treatment was safe for the patients.Analysis of different indicators of chronic in-flammation and aging included in initial, 24-hours, two weeks and three months protocolsshowed that stem cell treatment was safe for thepatients; there were no adverse reactions. More-over data from follow up protocols demonstratessignificant improvement in energy level, hair,nails growth and skin conditions.Conclusions: Intravenously administered UC-MSCs were safe and effective in the improvementof symptoms related to chronic inflammation.Further close monitoring and inclusion of morepatients are necessary to fully characterize theadvantages of UC-MSCs application in treatmentof symptoms related to chronic inflammation.
B.M. Mehling , L. Quartararo , M. Manvelyan, P. Wang, D.-C. Wu